NanoViricides (NYSE:NNVC) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of NanoViricides (NYSE:NNVC) in a research report report published on Monday morning. The brokerage issued a sell rating on the stock.

NanoViricides Stock Performance

NNVC opened at $1.17 on Monday. The company has a fifty day moving average price of $1.22 and a two-hundred day moving average price of $1.16. NanoViricides has a 52 week low of $1.00 and a 52 week high of $2.00. The firm has a market capitalization of $13.78 million, a PE ratio of -1.44 and a beta of 0.67.

NanoViricides (NYSE:NNVC) last released its earnings results on Wednesday, February 14th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.

Hedge Funds Weigh In On NanoViricides

Several institutional investors and hedge funds have recently made changes to their positions in NNVC. Two Sigma Investments LP acquired a new position in shares of NanoViricides in the 3rd quarter valued at $59,000. Renaissance Technologies LLC grew its holdings in shares of NanoViricides by 72.2% in the 1st quarter. Renaissance Technologies LLC now owns 76,800 shares of the company’s stock valued at $161,000 after buying an additional 32,200 shares during the period. Vanguard Group Inc. lifted its position in NanoViricides by 7.1% in the 3rd quarter. Vanguard Group Inc. now owns 458,072 shares of the company’s stock valued at $792,000 after acquiring an additional 30,194 shares in the last quarter. Millennium Management LLC lifted its position in NanoViricides by 59.1% in the 4th quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock valued at $75,000 after acquiring an additional 25,012 shares in the last quarter. Finally, Two Sigma Securities LLC bought a new stake in NanoViricides in the 2nd quarter valued at $28,000. Institutional investors and hedge funds own 10.30% of the company’s stock.

About NanoViricides

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.